NCT03963895View on ClinicalTrials.gov

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

December 29, 2020

Study Completion Date

December 29, 2020

Conditions
End Stage Renal DiseaseThrombosis
Interventions
DRUG

AB002 Dose 1

AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion

DRUG

AB002 Dose 2

AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion

DRUG

placebo

placebo administered on Day 1 as a single intravenous infusion

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

Sponsors

Lead Sponsor

Aronora, Inc.

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Aronora, Inc.

INDUSTRY